The TKI sevabertinib (Hyrnuo) is also approved for previously treated HER2-mutant disease, and is being evaluated in ...
By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has ...
Revolution Medicines thinks it could transform the treatment of pancreatic cancer – one of the hardest forms to treat – based ...
Zacks Investment Research on MSN
RVMD stock rallies 41% on positive phase III pancreatic cancer data
Shares of Revolution Medicines RVMD surged 41% after the company announced that its pivotal phase III RASolute 302 study ...
Revolution Medicines (RVMD) stock surged 38% after Phase 3 data showed daraxonrasib achieved 13.2 months survival vs. 6.7 months with chemotherapy.
As recognized leaders in cancer research, Huntsman Cancer Institute physicians and scientists are utilizing artificial intelligence (AI) to accelerate discoveries and improve patient care. When I was ...
An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...
We searched PubMed, Cochrane, CancerLit, Google Scholar, medRxiv, bioRxiv, UpToDate, TRIP database, and the ProQuest Dissertations and Theses Global databases to identify relevant articles. We ...
Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health. This voice experience is generated by AI. Learn more. This voice ...
Breast cancer remains the most common cancer among women globally, with cases expected to surge by 2050. Researchers analyzed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results